Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Siemens Healthcare: Michael Reitermann is the CEO of Siemens' U.S. health care business as of July 1. Since 2002, he has been running the firm's molecular imaging unit. Before that, he was a VP of Siemens' global angiography, fluoroscopy and X-ray business. Heinrich Kolem, who Reitermann is replacing, has been named global head of the angiography, fluoroscopy and X-ray division

You may also be interested in...



People In Brief

Intuitive Surgical succession: President and chief operating officer Gary Guthart will be promoted to CEO of robotic surgery juggernaut Intuitive Surgical on Jan. 1, the company said Oct. 23. Current Chairman and CEO Lonnie Smith will relinquish the executive role, but continue leading the firm's board of directors as of the New Year. Guthart, who will retain the president role, joined Intuitive in 1996. The personnel announcement came two days after the company announced its third quarter results (see Earnings Calls In Brief, p. 16)

People In Brief

Intuitive Surgical succession: President and chief operating officer Gary Guthart will be promoted to CEO of robotic surgery juggernaut Intuitive Surgical on Jan. 1, the company said Oct. 23. Current Chairman and CEO Lonnie Smith will relinquish the executive role, but continue leading the firm's board of directors as of the New Year. Guthart, who will retain the president role, joined Intuitive in 1996. The personnel announcement came two days after the company announced its third quarter results (see Earnings Calls In Brief, p. 16)

Luminex Builds Genetic Test Portfolio Via Tm Bioscience Acquisition

Luminex's purchase of DNA-based test maker Tm Bioscience gives the firm full ownership of comprehensive molecular diagnostic kits previously produced collaboratively by the companies

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel